Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving leading biopharmaceutical companies globally:

Dow
Express Scripts
AstraZeneca
Moodys
Mallinckrodt
McKinsey

Last Updated: December 9, 2019

DrugPatentWatch Database Preview

Drugs in Development Information for MEK162

Join the DrugPatentWatch Referral Program
Get access to a free drug patent landscape report or a free one-month subscription

« Back to Dashboard

What is the drug development status for MEK162?

MEK162 is an investigational drug.

There have been 52 clinical trials for MEK162. The most recent clinical trial was a Phase 2 trial, which was initiated on July 1st 2013.

The most common disease conditions in clinical trials are Melanoma, Lung Neoplasms, and Carcinoma, Non-Small-Cell Lung. The leading clinical trial sponsors are Array BioPharma, National Cancer Institute (NCI), and Pfizer.

There are forty-seven US patents protecting this investigational drug and four hundred and seventy-five international patents.

Recent Clinical Trials for MEK162
TitleSponsorPhase
Binimetinib and Hydroxychloroquine in Treating Patients With KRAS Mutant Metastatic Pancreatic CancerNational Cancer Institute (NCI)Phase 1
Binimetinib and Hydroxychloroquine in Treating Patients With KRAS Mutant Metastatic Pancreatic CancerM.D. Anderson Cancer CenterPhase 1
Encorafenib, Binimetinib, and Nivolumab in Treating Patients With Microsatellite Stable BRAFV600E Metastatic Colorectal CancerArray BioPharmaPhase 1/Phase 2

See all MEK162 clinical trials

Clinical Trial Summary for MEK162

Top disease conditions for MEK162
Top clinical trial sponsors for MEK162

See all MEK162 clinical trials

US Patents for MEK162

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
MEK162   Start Trial Compounds and compositions as protein kinase inhibitors Array BioPharma Inc. (Boulder, CO)   Start Trial
MEK162   Start Trial Benzothiophene-based selective estrogen receptor downregulators The Board of Trustees of the University of Illinois (Urbana, IL)   Start Trial
MEK162   Start Trial Solid forms of isoquinolinones, and process of making, composition comprising, and methods of using the same Infinity Pharmaceuticals, Inc. (Cambridge, MA)   Start Trial
MEK162   Start Trial Benzothiophene estrogen receptor modulators G1 Therapeutics, Inc. (Research Park Triangle, NC)   Start Trial
MEK162   Start Trial Anti-neoplastic combinations and dosing regimens using CDK4/6 inhibitor compounds to treat RB-positive tumors GI Therapeutics, Inc. (Research Triangle Park, NC)   Start Trial
MEK162   Start Trial Heterocyclic compounds and uses thereof Infinity Pharmaceuticals, Inc. (Cambridge, MA)   Start Trial
MEK162   Start Trial Generation of muscle lineage cells and therapeutic uses thereof GENEA BIOCELLS USA (HOLDINGS), INC. (San Diego, CA)   Start Trial
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for MEK162

Drugname Country Document Number Estimated Expiration Related US Patent
MEK162 Argentina 077975 2029-08-28   Start Trial
MEK162 Australia 2010286569 2029-08-28   Start Trial
MEK162 Canada 2771775 2029-08-28   Start Trial
MEK162 China 102725283 2029-08-28   Start Trial
MEK162 China 103896921 2029-08-28   Start Trial
MEK162 Colombia 6612222 2029-08-28   Start Trial
MEK162 Costa Rica 20120102 2029-08-28   Start Trial
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Colorcon
Moodys
McKinsey
Baxter
Express Scripts
Medtronic

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.